Oropharyngeal Cancer Rising In Incidence and Costs to Over $140,000

MedicalResearch.com Interview with:

David R. Lairson, PhD Professor of Health Economics Division of Management Policy and Community Health Co-Director, Center for Health Services Research School of Public Health The University of Texas Health Science Center at Houston (UTHealth)

Dr. Lairson

David R. Lairson, PhD
Professor of health economics
Department of Management, Policy, and Community Health
The University of Texas Health Science Center at Houston (UTHealth) School of Public Health

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: The study of oropharyngeal cancer treatment cost was initiated by the Head and Neck Cancer Surgery Department at the University of Texas MD Anderson Cancer Center as part of a larger study of the economic and health consequences of human papillomavirus (HPV) related conditions in Texas.  State specific information is required for policy-makers to consider future investments in cancer prevention based on HPV immunization and cancer screening.  The cost estimates at $140,000 per case for the first two years of treatment are substantially higher than previous estimates.  They indicate the potential savings associated with cancer prevention and partially justify increased investment in immunization efforts.

Continue reading

Increase in HPV+ Oropharyngeal Cancers Suggests Both Sexes Should Be Vaccinated

MedicalResearch.com Interview with:

Steven Habbous MSc, PhD candidate Ontario Cancer Institute Scarborough, Ontario, Canada

Steven Habbous

Steven Habbous MSc, PhD candidate
Ontario Cancer Institute
Scarborough, Ontario, Canada

MedicalResearch.com: What is the background for this study?

Response: Human papillomavirus (HPV) is a strong risk factor for oropharyngeal cancers (a subset of head and neck cancers). Because HPV-related oropharyngeal cancers generally respond well to treatment and may be prevented through HPV vaccination, it is critical to be able to accurately estimate the incidence and prevalence of this disease. Only recently, however, has testing for HPV become routine at most cancer centres across Canada.  As a result, attempts to estimate the growth of HPV-related oropharyngeal cancer over time may be inaccurate.

Continue reading

Post-Op Radiotherapy Improved Survival In Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

MedicalResearch.com Interview with:

Michelle M. Chen, MD/MHS Department of Otolaryngology- Head and Neck Surgery Stanford University

Dr. Michelle Chen

Michelle M. Chen, MD/MHS
Department of Otolaryngology- Head and Neck Surgery
Stanford University 

MedicalResearch.com: What is the background for this study? What are the main findings?

Response: The benefit of post-operative radiotherapy (PORT) for patients with T1-T2 N1 oral cavity and oropharyngeal cancer without adverse pathologic features is unclear. Starting in 2014, the national guidelines no longer recommended consideration of post-operative radiotherapy for N1 oropharyngeal cancer patients, but left it as a consideration for N1 oral cavity cancer patients. We found that post-operative radiotherapy was associated with improved survival in both oral cavity and oropharyngeal cancers, particularly in patients younger than 70 years of age and those with T2 disease.

Continue reading

Diabetes Raises Risk of Oral Cancers

MedicalResearch.com Interview with:
Yung-Song Lin MD
Chi Mei Medical Center
Taipei Medical University

Medical Research: What are the main findings of the study?

Dr. Lin: The risks of developing oral cavity cancer, oropharyngeal cancer, and nasopharyngeal cancer (NPC) were significantly higher in patients with diabetes.
Continue reading

Time to First Cigarette and 4-(Methylnitrosamino)-1-(3-Pyridyl)-1-Butanol (NNAL) Levels in Adult Smokers; National Health and Nutrition Examination Survey (NHANES), 2007–2010

MedicalResearch.com Author Interview:
Dr. Steven A. Branstetter, PhD The Pennsylvania State University, 315 E. HHD, University Park, PA 16810.Dr. Steven A. Branstetter, PhD
The Pennsylvania State University, 315 E. HHD, University Park, PA 16810.

MedicalResearch.com: What are the main findings of the study?

Dr. Branstetter: This study demonstrated that the time to the first cigarette of the day after waking is associated with increased levels of a NNAL, a metabolite of a powerful tobacco-specific carcinogen, NNK — even after controlling for the total number of cigarettes smoked per day.

For years, the time to the first cigarette of the day after waking was one of several questions assessing nicotine dependence on the Fagerstrom Test for Nicotine Dependence (FTND), the gold standard questionnaire int he field. Over time, it was found that much of the predictive validity of the FTND was due to the time to first cigarette item. Researchers have found that single time to first cigarette item was highly correlated with other measures of nicotine dependence, and was predictive of more difficulty quitting smoking and increased intake of nicotine. Our current study demonstrates that this behavioral measure, is predictive of exposure to the cancer-causing components of cigarettes, regardless of the total number of cigarettes smoked per day. The results suggest that researchers, clinicians and smokers can assess the level of nicotine dependence and potential cancer risk by looking at the time to the first cigarette of the day after waking.
Continue reading